Medgenics (NASDAQ: GNMX) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.
Earnings and Valuation
This table compares Medgenics and VBI Vaccines’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|VBI Vaccines||$550,000.00||424.63||-$23.20 million||N/A||N/A|
Volatility and Risk
Medgenics has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 2.3, indicating that its share price is 130% more volatile than the S&P 500.
Insider & Institutional Ownership
16.6% of Medgenics shares are owned by institutional investors. Comparatively, 23.7% of VBI Vaccines shares are owned by institutional investors. 15.2% of Medgenics shares are owned by company insiders. Comparatively, 34.1% of VBI Vaccines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares Medgenics and VBI Vaccines’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations for Medgenics and VBI Vaccines, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Medgenics currently has a consensus target price of $4.25, suggesting a potential upside of 88.05%. VBI Vaccines has a consensus target price of $10.50, suggesting a potential upside of 186.89%. Given VBI Vaccines’ stronger consensus rating and higher probable upside, analysts clearly believe VBI Vaccines is more favorable than Medgenics.
VBI Vaccines beats Medgenics on 10 of the 11 factors compared between the two stocks.
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
About VBI Vaccines
VBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.
Receive News & Ratings for Medgenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics and related companies with MarketBeat.com's FREE daily email newsletter.